{'52WeekChange': 0.07774794,
 'SandP52WeekChange': 0.0644362,
 'address1': '909 Davis Street',
 'address2': 'Suite 600',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.03,
 'askSize': 1000,
 'averageDailyVolume10Day': 249275,
 'averageVolume': 430090,
 'averageVolume10days': 249275,
 'beta': 1.477393,
 'beta3Year': None,
 'bid': 4.02,
 'bidSize': 4000,
 'bookValue': 2.69,
 'category': None,
 'circulatingSupply': None,
 'city': 'Evanston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.28,
 'dayLow': 4,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.097,
 'enterpriseToRevenue': 17.38,
 'enterpriseValue': 62515388,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 4.2897143,
 'fiftyTwoWeekHigh': 5.28,
 'fiftyTwoWeekLow': 1.6,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 22761584,
 'forwardEps': -1.32,
 'forwardPE': -3.0454545,
 'fromCurrency': None,
 'fullTimeEmployees': 43,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.05037,
 'heldPercentInstitutions': 0.53815,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/aptinyx.com',
 'longBusinessSummary': 'Aptinyx Inc., a clinical-stage biopharmaceutical '
                        'company, focuses on the discovery, development, and '
                        'commercialization of novel, proprietary, and '
                        'synthetic small molecules for the treatment of brain '
                        'and nervous system disorders. The company is '
                        'developing NYX-2925, which is in Phase II clinical '
                        'development for the treatment of painful diabetic '
                        'peripheral neuropathy, as well as in Phase II '
                        'clinical trial for treating fibromyalgia. It is also '
                        'developing NYX-783, an N-methyl-D-aspartate receptors '
                        '(NMDAr) modulator that is in Phase I clinical trial '
                        'to treat post-traumatic stress disorder; and NYX-458, '
                        'an NMDAr modulator, which is in Phase I clinical '
                        "study for the treatment of Parkinson's disease "
                        'cognitive impairment. The company has a research '
                        'collaboration agreement with Allergan plc to develop '
                        'a compound for the treatment of major depressive '
                        'disorder. Aptinyx Inc. was founded in 2015 and is '
                        'headquartered in Evanston, Illinois.',
 'longName': 'Aptinyx Inc.',
 'market': 'us_market',
 'marketCap': 183048288,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_336341295',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -55409000,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.24,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '847-871-0377',
 'previousClose': 4.26,
 'priceHint': 4,
 'priceToBook': 1.4944237,
 'priceToSalesTrailing12Months': 50.889153,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.28,
 'regularMarketDayLow': 4,
 'regularMarketOpen': 4.24,
 'regularMarketPreviousClose': 4.26,
 'regularMarketPrice': 4.24,
 'regularMarketVolume': 145338,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 45534400,
 'sharesPercentSharesOut': 0.0224,
 'sharesShort': 1023316,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 306140,
 'shortName': 'Aptinyx Inc.',
 'shortPercentOfFloat': 0.038900003,
 'shortRatio': 1.97,
 'startDate': None,
 'state': 'IL',
 'strikePrice': None,
 'symbol': 'APTX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.532,
 'twoHundredDayAverage': 3.4727337,
 'volume': 145338,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.aptinyx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '60201'}